Clinical Trials Browser

Phase 2 × Urologic Neoplasms × Sunitinib × Clear all

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Urologic Neoplasms